SEC settles charges with Kiromic Biopharma for misleading investors, issues penalties for former execs
The regulatory agency charged Kiromic Biopharma and its former CEO and CFO for their roles in disclosures related to drug candidates’ FDA status.
Building "Bridges" Across the Bayou City!
The regulatory agency charged Kiromic Biopharma and its former CEO and CFO for their roles in disclosures related to drug candidates’ FDA status.